Avanos Medical Inc (AVNS) — 13F Filings Explorer (Q2 2026)

Avanos Medical (AVNS) disclosed in this 8-K that it entered into a new credit agreement tied to the closing of a merger and then succeeded to the borrower's rights and obligations under the agreement. The facility includes an initial term loan of $675.0 million, $100.0 million of delayed-draw term loan commitments, and a $100.0 million revolving credit facility, maturing July 27, 2033. The excerpt also lists the termination of a material definitive agreement, but no details for that item are included in the provided text.

Avanos Medical held a special shareholder meeting on July 22, 2026, where stockholders voted overwhelmingly to approve the merger that will make the company a wholly-owned subsidiary of A-AV Holdco I. Over 35 million shares were cast in favor, with only about 32,000 against. They also passed a non-binding advisory vote on merger-related executive compensation, though that vote saw more opposition—about 4.2 million shares. A quorum of 75% was present.

Avanos Medical filed an 8-K on July 14, 2026, to supplement its proxy statement for the pending merger with A-AV Holdco I, Inc. Two shareholder lawsuits and several demand letters alleged that the proxy statement omitted key details about the deal. Although Avanos disagrees with the claims, it voluntarily added more disclosures—including that its financial advisor UBS could receive up to $5 million in fees—to avoid delays. The board continues to recommend that stockholders vote in favor of the merger.

No AI summary for this filing type